Efficacy and safety of individualized rituximab in proliferative lupus nephritis

医学 狼疮性肾炎 内科学 美罗华 耐火材料(行星科学) 不利影响 血液透析 胃肠病学 强的松 肾病科 完全缓解 环磷酰胺 外科 化疗 疾病 淋巴瘤 物理 天体生物学
作者
Yingxuan Hao,Yanhong Guo,Lu Yu,Liuwei Wang,Zihan Zhai,Lin Tang
出处
期刊:Research Square - Research Square
标识
DOI:10.21203/rs.3.rs-3406954/v1
摘要

Abstract The dosage, efficacy and safety of Rituximab (RTX) in the treatment of proliferative lupus nephritis (PLN) have not been fully investigated. We collected the data episodes from January 2017 to July 2023 of patients with PLN who were hospitalized in the Department of Nephrology of the First Affiliated Hospital of Zhengzhou University and treated with RTX, and the renal remission, recurrence and adverse reactions after RTX treatment were analyzed retrospectively. A total of 22 patients were enrolled, including 7 patients who were treated as a naive and 15 relapsed/refractory patients, 4 patients required hemodialysis on admission. After the first treatment of RTX, a total of 21(95.45%) patients achieved B cell depletion, and a total of 15 patients (68.18%) achieved complete response (CR). The annual average frequency of relapse per individual in the maintenance remission period in 15 refractory/relapsing patients decreased from (0.494±0.346) times to (0.026±0.010) time (P<0.001), and the maintenance doses of prednisone decreased from (14.17±9.39) mg/day [ 20.0(12.3,40.0)months] to (8.67±5.97) mg/d[ 12.0(10.0,15.0)months] (P=0.040). Infection occurred in 3 patient within the first 3 months after RTX treatment and recovered after treatment, 3 cases were removed from hemodialysis, and no patient died. In conclusion, RTX can effectively treat PLN, reduce frequency of recurrences and decrease the dose of glucocorticoids, without increasing the occurrence of increased infection risks.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
ZZICU完成签到,获得积分10
1秒前
yun尘世发布了新的文献求助10
1秒前
量子星尘发布了新的文献求助10
2秒前
2秒前
4秒前
罗拉发布了新的文献求助10
4秒前
5秒前
5秒前
鱼e完成签到,获得积分10
7秒前
7秒前
8秒前
8秒前
song发布了新的文献求助10
10秒前
ding应助时尚初之采纳,获得10
10秒前
罗拉完成签到,获得积分10
10秒前
10秒前
11秒前
yun尘世完成签到,获得积分10
12秒前
12秒前
自信南霜完成签到,获得积分10
12秒前
tingting9完成签到,获得积分10
15秒前
15秒前
16秒前
卡布奇诺完成签到,获得积分10
16秒前
13223456发布了新的文献求助10
16秒前
青山落日秋月春风完成签到,获得积分10
18秒前
19秒前
20秒前
20秒前
小马甲应助动听的雅绿采纳,获得30
21秒前
1177发布了新的文献求助10
23秒前
23秒前
喜喵喵完成签到,获得积分10
24秒前
24秒前
24秒前
24秒前
11关注了科研通微信公众号
25秒前
123456完成签到,获得积分10
26秒前
时尚初之发布了新的文献求助10
26秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989242
求助须知:如何正确求助?哪些是违规求助? 3531393
关于积分的说明 11253753
捐赠科研通 3270010
什么是DOI,文献DOI怎么找? 1804868
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136